Trials / Completed
CompletedNCT02836821
Effect of Rifampicin on the Pharmacokinetics of Apatinib
Effect of Rifampicin on the Pharmacokinetics of Apatinib in Chinese Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with rifampicin. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with rifampicin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib Mesylate Tablets | apatinib was administered in the morning after an overnight fast of at least 10 h |
| DRUG | Rifampicin Capsules | rifampicin was administered in the morning 2 hours after breakfast |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2016-07-19
- Last updated
- 2017-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02836821. Inclusion in this directory is not an endorsement.